NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01696084,Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia,https://clinicaltrials.gov/study/NCT01696084,301,COMPLETED,To confirm the efficacy of CPX-351 compared to 7+3 as first line therapy in elderly patients (60-75 yrs) with high risk (secondary) Acute Myeloid Leukemia. The primary efficacy endpoint will be overall survival.,YES,High Risk Acute Myeloid Leukemia,DRUG: CPX-351|DRUG: 7+3 (cytarabine and daunorubicin),"Overall Survival, Overall survival was measured from the date of randomization to death from any cause, subjects not known to have died by the last follow-up were censored on the date they were last known to be alive., From the date of randomization to death from any cause","Proportion of Subjects With a Response, Complete Remission (CR), Post Induction|Event-free Survival, All randomized subjects were assessed for event-free survival (EFS). EFS was defined as the time from study randomization to the date of induction treatment failure (persistent disease), relapse from CR or CRi or death from any cause, whichever came first. Subjects alive and not known to have any of these events were censored on thee date they were last examined on study., From the date of randomization to the date that persistent disease was documented or the date of relapse after CR or death, whichever came first|Remission Duration, Only subjects achieving CR or CRi were assessed for remission duration., From the date of achievement of a remission until the date of relapse or death from any cause|Rate of Achieving Morphologic Leukemia-free State, All randomized subjects with at least 1 evaluable postrandomization bone marrow assessment performed on or after Day 14 after the last induction were assessed for MLFS., Day 14|Proportion of Subjects Receiving a Stem Cell Transplant, The number and percentage of subjects transferred for HSCT after induction treatment was recorded., Post Induction",,Jazz Pharmaceuticals,The Leukemia and Lymphoma Society,ALL,"ADULT, OLDER_ADULT",PHASE3,309,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,CLTR0310-301,2012-12-13,2015-12-31,2015-12-31,2012-09-28,2017-10-02,2020-08-10,"University of Alabama at Birmingham, Birmingham, Alabama, 35294, United States|UCLA, Los Angeles, California, 90095, United States|University of CA San Diego, San Diego, California, 92037-0706, United States|Stanford University, Stanford, California, 94305, United States|Yale University, New Haven, Connecticut, 06510, United States|University of Florida, Gainesville, Florida, 32611, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, 33612, United States|Northside Hospital, Atlanta, Georgia, 30342, United States|Northwestern University, Chicago, Illinois, 60208, United States|Rush University Medical Center, Chicago, Illinois, 60612, United States|University of Chicago, Chicago, Illinois, 60637, United States|Franciscan St. Francis Health, Indianapolis, Indiana, 46237, United States|University of Kansas Medical Center, Kansas City, Kansas, 66160, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States|University of Michigan, Ann Arbor, Michigan, 48109, United States|University of Minnesota, Minneapolis, Minnesota, 55455, United States|University of Missouri, Columbia, Missouri, 65211, United States|Washington University, Saint Louis, Missouri, 63110, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States|Montefiore Medical Center, Bronx, New York, 10467, United States|North Shore LIJ Health System, Long Island City, New York, United States|Columbia University, New York, New York, 10032, United States|Cornell U, Weill Medical College, New York, New York, 10065, United States|New York Medical College, Valhalla, New York, 10595, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599-1651, United States|Duke University Medical Center, Durham, North Carolina, 27710, United States|Wake Forest University Health Services, Winston-Salem, North Carolina, 27157, United States|Providence Portland Medical Center, Portland, Oregon, 97213, United States|Oregon Health and Science University, Portland, Oregon, 97239, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111, United States|UPMC, Pittsburgh, Pennsylvania, 15219, United States|Medical University of South Carolina, Charleston, South Carolina, 29425, United States|Sarah Cannon Research Institute, Nashville, Tennessee, 37203, United States|Vanderbilt University, Nashville, Tennessee, 37232, United States|Baylor Research Insitute, Dallas, Texas, 75246, United States|M.D. Anderson Cancer Center, Houston, Texas, 770303, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, 98109, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States|University of Alberta Hospital, Edmonton, Alberta, T6G 2C8, Canada|British Columbia Cancer Center, Vancouver, British Columbia, V5Z 1M9, Canada|Princess Margaret Hospital, Toronto, Ontario, M5G2M9, Canada|Hopital Maisonneuve-Rosemont, Montreal, Quebec, Canada",
